에난타제약(주)
US ˙ NasdaqGS ˙ US29251M1062

SecurityENTA / Enanta Pharmaceuticals, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership309,511 shares
Latest Disclosed Value $ 3,909,132
Morgan Stanley reports 8.95% decrease in ownership of ENTA / Enanta Pharmaceuticals, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 309,511 shares of Enanta Pharmaceuticals, Inc. (US:ENTA) valued at $3,909,124 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 339,918 shares of Enanta Pharmaceuticals, Inc.. This represents a change in shares of -8.95% during the quarter. The current value of the position is $3,630,564 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 309,511 -30,407 -8.95 3,909 -27.07 0.0002
2026-05-27 2025-12-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 339,918 57,287 20.27 5,361 58.44 0.0003
2026-02-13 2025-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 339,918 57,287 5,361 0.0003
2026-05-27 2025-09-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 282,631 -3,895 -1.36 3,383 56.19 0.0002
2025-11-14 2025-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 282,631 -3,895 3,383 0.0002
2025-08-15 2025-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 286,526 -198,965 -40.98 2,166 -19.15 0.0001
2025-05-15 2025-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 485,491 -736,104 -60.26 2,680 -61.86 0.0002
2025-05-15 2024-12-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 1,221,595 118,743 10.77 7,024 -38.52 0.0005
2025-02-14 2024-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,221,595 118,743 7,024 0.0005
2025-05-14 2024-09-30 13F/A-2 ENANTA PHARMACEUTICALS COM 29251M106 1,102,852 -353,707 -24.28 11,426 -39.52 0.0008
2025-02-14 2024-09-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 1,102,852 -353,707 11,426 0.0008
2024-11-14 2024-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 1,102,852 -353,707 11,426 0.0001
2025-05-14 2024-06-30 13F/A-2 ENANTA PHARMACEUTICALS COM 29251M106 1,456,559 -588,586 -28.78 18,892 -47.10 0.0015
2024-10-17 2024-06-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 1,456,559 -588,586 18,892 0.0015
2024-08-14 2024-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 1,456,559 -588,586 18,892 0.0015
2024-10-17 2024-03-31 13F/A-2 ENANTA PHARMACEUTICALS COM 29251M106 2,045,145 872,087 74.34 35,708 223.50 0.0029
2024-08-16 2024-03-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 2,045,145 872,087 35,708 0.0003
2024-05-15 2024-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,045,145 872,087 35,708 0.0029
2024-08-16 2023-12-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 1,173,058 608,492 107.78 11,038 75.04 0.0010
2024-02-13 2023-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,173,058 608,492 11,038 0.0010
2023-11-15 2023-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 564,566 257,264 83.72 6,306 -4.11 0.0006
2023-08-14 2023-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 307,302 175,354 132.90 6,576 23.26 0.0006
2023-05-15 2023-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 131,948 -6,577 -4.75 5,336 -17.21 0.0006
2023-02-14 2022-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 138,525 -43,149 -23.75 6,444 -31.61 0.0007
2022-11-14 2022-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 181,674 -63,200 -25.81 9,422 -18.61 0.0013
2022-10-27 2022-06-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 244,874 78,326 47.03 11,576 -2.35 0.0015
2022-08-15 2022-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 244,874 78,326 11,576 0.0003
2022-10-27 2022-03-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 166,548 40,479 32.11 11,854 25.75 0.0016
2022-05-13 2022-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 166,548 40,479 11,854 0.0016
2022-02-14 2021-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 126,069 -36,163 -22.29 9,427 2.28 0.0012
2021-11-15 2021-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 162,232 -13,975 -7.93 9,217 18.84 0.0012
2021-08-23 2021-06-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 176,207 30,356 20.81 7,756 7.81 0.0010
2021-08-16 2021-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 176,207 30,356 7,756 0.0002
2021-05-17 2021-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 145,851 -12,305 -7.78 7,194 8.05 0.0011
2021-02-16 2020-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 158,156 67,901 75.23 6,658 61.13 0.0010
2020-11-13 2020-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 90,255 27,983 44.94 4,132 32.14 0.0008
2020-08-14 2020-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 62,272 -5,896 -8.65 3,127 -10.81 0.0007
2020-05-26 2020-03-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 68,168 -167,990 -71.13 3,506 -75.97 0.0010
2020-05-15 2020-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 68,168 -167,990 3,506 269.3339
2020-02-14 2019-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 236,158 69,848 42.00 14,590 46.00 0.0034
2019-11-14 2019-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 166,310 57,346 52.63 9,993 8.69 0.0026
2019-08-14 2019-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 108,964 31,335 40.37 9,194 23.98 0.0024
2019-05-15 2019-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 77,629 -114,507 -59.60 7,416 -45.50 0.0021
2019-02-14 2018-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 192,136 152,246 381.66 13,608 299.06 0.0041
2019-04-23 2018-09-30 13F/A-2 ENANTA PHARMACEUTICALS COM 29251M106 39,890 -11,877 -22.94 3,410 -43.17 0.0009
2018-11-20 2018-09-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 39,890 0 3,410 0.0009
2018-11-14 2018-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 39,890 -11,877 3,410
2019-04-23 2018-06-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 51,767 -5,808 -10.09 6,000 28.78 0.0016
2018-08-14 2018-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 51,767 -5,808 6,000
2019-04-23 2018-03-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 57,575 10,806 23.11 4,659 69.73 0.0013
2018-05-14 2018-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 57,575 10,806 4,659
2019-04-23 2017-12-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 46,769 12,774 37.58 2,745 72.53 0.0008
2018-02-14 2017-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 46,769 12,774 2,745
2017-11-14 2017-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 33,995 3,155 10.23 1,591 43.33 0.0005
2017-08-11 2017-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 30,840 -7,586 -19.74 1,110 -6.25 0.0003
2017-05-22 2017-03-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 38,426 -11,834 -23.55 1,184 -29.65 0.0004
2017-05-12 2017-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 38,426 1,184
2017-02-22 2016-12-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 50,260 45,008 856.97 1,683 1,102.14 0.0006
2017-02-13 2016-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 50,260 1,683
2016-11-10 2016-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 5,252 -3,674 -41.16 140 -28.57 0.0000
2016-08-12 2016-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 8,926 2,044 29.70 196 -2.97 0.0001
2016-05-12 2016-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 6,882 -3,872 -36.01 202 -43.26 0.0001
2016-02-09 2015-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 10,754 6,655 162.36 356 140.54 0.0001
2016-02-08 2015-09-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 4,099 -917 -18.28 148 -34.51 0.0001
2015-11-09 2015-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 4,099 148
2015-08-12 2015-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 5,016 -3,679 -42.31 226 -15.04 0.0001
2015-05-14 2015-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 8,695 -2,780 -24.23 266 -54.45 0.0001
2015-02-13 2014-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 11,475 6,957 153.98 584 226.26 0.0002
2014-12-16 2014-09-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 4,518 -701 -13.43 179 -13.94 0.0001
2014-11-14 2014-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 4,518 179
2014-05-13 2014-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 5,219 -1,006 -16.16 208 22.35 0.0001
2014-02-13 2013-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 6,225 -37,453 -85.75 170 -78.01 0.0001
2013-08-08 2013-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 43,678 43,678 773 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.